Search results
Results from the WOW.Com Content Network
Zerodha was founded in August 2010 by brothers Nithin and Nikhil Kamath. The name Zerodha, indicates a combination of words for the company's ideals: zero and rodha, the Sanskrit word for 'barrier'. [10] [11] In 2019, Zerodha became the largest retail stockbroker in India by active client base, overtaking ICICI Securities. It contributed up to ...
A demat account is an Indian term for a dematerialized account that holds financial securities (equity or debt) digitally for traded shares in the share market. In India, demat accounts are maintained by two depository organizations: the National Securities Depository Limited and the Central Depository Services Limited .
A demat account is opened on the same lines as that of a Bank Account. Prescribed Account opening forms are available with the DP, needs to be filled in. Standard Agreements are to be signed by the Client and the DP, which details the rights and obligations of both parties.
Learn more about ID Protection by AOL, the plan designed to help protect your identity, privacy and online reputation so you can shop, bank, socialize, and surf online with greater peace of mind.
He is the co-founder of Zerodha, a retail stockbroker, and True Beacon, an asset management company. [3] [4] [5] Kamath is a part of the 2024 Forbes World Billionaires List with a net worth of $3.1 billion. [6] [7] He, along with his brother Nithin, is also part of Forbes' list of India’s 100 Richest for 2024. [8]
CDSL is the largest depository in India in terms of number of demat accounts opened. In February, CDSL became the first depository in India to open 60 million active demat accounts. [4] As of March 2022, the depository holds assets worth ₹ 37.2 trillion, [5] with over 580 depository participants associated with CDSL. [6]
It was established based on a suggestion by a national institution responsible for the economic development of India. At the end of 2023, its demat accounts held assets worth ₹398 Lakh Crore ($4.7 trillion). [3] [4] [5] [6]
In 1999, Johnson & Johnson had signed a contract with a company called Excerpta Medica. Its specialty was medical marketing. Its sub-specialty was producing ghostwritten, data-filled studies on the efficacy and safety of a client’s drugs, finding the right academic scholars to be listed as the authors and then placing the articles in prestigious academic journals.